No Detail Found!

Prolonged Disease Control with Nivolumab in Metastatic Lung Adenocarcinoma during Immunotherapy Era.

Author(s)
Murat Sari Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey
Pinar Saip Department of Medical Oncology, Istanbul University Institute of Oncology, Istanbul, Turkey
Abstract
Immune checkpoint inhibitors have taken an important place in the field of oncologic immunotherapy, especially for patients in whom conventional treatment regimens have failed. Nivolumab prevents programmed cell death 1 (PD-1) and programmed cell death ligand-1 (PD-L1) binding, resulting in blockage of the inhibitory signal and thus facilitating an immunologic antitumor response. Nivolumab has been shown to be effective in thoracic malignancies, including non-small cell lung cancer (NSCLC). Here is a case of 52-year male patient with metastatic lung adenocarcinoma progressing after 4 cycles of chemotherapy. We started nivolumab q2 weeks therapy. Firstly, his dyspnea relieved, carcinoembryonic antigen (CEA) and C-reactive protein (CRP) levels regressed, and then their levels remained constant at a stable level. Radiologically stable response was seen. Progression was seen after about one and half year. Patient died in a short time after progression. In conclusion, this observation provides a strong indication of the potential value of immune checkpoint inhibitors for the management of metastatic lung cancers.
Publication Details
Page(s) 891-892
DOI DOI not available
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 28, Issue: 11, Year: 2018

Request the full text from PASTIC

References
BorghaeiH,LynchTJ,RizviNA, 2013.A phase III comparative study of nivolumab (anti-PD-1; BMS-963558; ONO-4538) versus docetaxel in patients (pts) with previously treated advanced/ metastatic nonsquamous non-small-cell lung cancer (NSCLC),J Clin Oncol 31 TPS8121 -
DominguesD,TurnerA,SilvaMD, 2014.Immunotherapy and lung cancer: current developments and novel targeted therapies,Immunotherapy 6 1221 -35
RizviNA,MazieresJ,PlanchardD, 2015.Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial,Lancet Oncol 16 257 -65
BrahmerJ,ReckampKL,BaasP, 2015.Nivolumab versus docetaxel in advanced squamous non-small cell lung cancer,N Engl J Med 373 123 -35
KazandjianD,KhozinS,BlumenthalG, 2016.Benefit-risk summary of nivolumab for patients with metastatic squamous cell lung cancer after platinum-based chemotherapy a report from the US food and drug administration,JAMA Oncol 2 118 -22
0

Citations

0

Downloads

54

Views